Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate-Dose Cytarabine Induction in Adult AML
NCT03021330Phase 3Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2017
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2017; status: active, not recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03021330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021330.